At least four activist investors held stakes in Kenvue (KVUE) and D.E. Shaw, one of the Tylenol-maker’s largest shareholders, stood to suffer some of the biggest losses with a stake of around 3%, people familiar with the matter told The Wall Street Journal’s Ben Dummett and Lauren Thomas. However, because of Kimberly-Clark’s (KMB) buyout offer, the activist investor is set to break even on its investment, the sources said. Toms Capital Investment Management is another big shareholder in Kenvue with a more than 3% stake and Toms plans to keep holding its Kenvue shares after Monday’s deal, some of the sources said. Other activist investors exposed to Kenvue include Starboard Value and Dan Loeb’s Third Point, the WSJ noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Early notable gainers among liquid option names on November 3rd
- Morning Movers: Kenvue surges, Kimberly-Clark sinks after tie up
- Kimberly-Clark says ‘carefully considered’ risks, opportunities in Kenvue deal
- M&A: Diaper Group Kimberly-Clark Leaks 15% After $48.7B Purchase of Tylenol Maker Kenvue
- Kenvue Merges with Kimberly-Clark in $48.7B Deal